Released Aug 6, 2020, after the close
10-Q filed Aug 7, 2020, 38 days after period end · 0001162194-20-000093
Q2 2020 · 10-Q
Revenue$26.06M$26.06M −7.6% vs Q2 2019−5.6% vs Q1 2020
Net Income-$13.02M-$13.02M N/M vs Q2 2019N/M vs Q1 2020
EPS Diluted-$0.18-$0.18 N/M vs Q2 2019N/M vs Q1 2020
Gross Profit$11,825,000−23.0%
Operating Income-$13,726,000N/M
Operating Cash Flowderived-$2,790,000N/M
Free Cash Flowderived-$3,431,000N/M
Margins · derived
Gross margin45.4%−9.1 pt vs Q2 2019
Operating margin-52.7%−0.8 pt vs Q2 2019
Net margin-49.9%−1.2 pt vs Q2 2019
What the release said
The release
Same quarter
| Metric | Q2 2020 | Q2 2019 | Q2 2018 | Q2 2017 |
|---|---|---|---|---|
| Revenue | $26.06M | $28.20M | $26.43M | $23.91M |
| Net Income | -$13.02M | -$13.75M | -$16.24M | -$16.93M |
| EPS Diluted | -$0.18 | -$0.20 | -$0.42 | -$0.58 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR